ADMA Biologics (NASDAQ:ADMA) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright restated their buy rating on shares of ADMA Biologics (NASDAQ:ADMA) in a report published on Monday, Marketbeat.com reports. HC Wainwright currently has a $18.00 price target on the biotechnology company’s stock.

Other equities analysts have also issued research reports about the company. Mizuho raised their price objective on ADMA Biologics from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Thursday, June 20th. Cantor Fitzgerald reissued an “overweight” rating and set a $20.00 price objective on shares of ADMA Biologics in a research report on Friday, September 20th. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, ADMA Biologics presently has an average rating of “Buy” and an average target price of $15.50.

ADMA Biologics Stock Performance

Shares of ADMA stock opened at $16.12 on Monday. The stock has a fifty day moving average of $18.09 and a 200 day moving average of $12.59. ADMA Biologics has a 52 week low of $3.06 and a 52 week high of $21.13. The firm has a market capitalization of $3.74 billion, a price-to-earnings ratio of -806.00 and a beta of 0.62. The company has a quick ratio of 2.80, a current ratio of 6.87 and a debt-to-equity ratio of 0.74.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Thursday, August 8th. The biotechnology company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.08 by $0.05. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. The company had revenue of $107.20 million during the quarter, compared to analyst estimates of $86.44 million. During the same quarter last year, the firm posted ($0.02) earnings per share. The firm’s revenue was up 78.4% on a year-over-year basis. As a group, research analysts expect that ADMA Biologics will post 0.49 earnings per share for the current year.

Insider Buying and Selling at ADMA Biologics

In other news, CEO Adam S. Grossman sold 236,889 shares of the firm’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the completion of the transaction, the chief executive officer now directly owns 2,059,726 shares in the company, valued at $36,436,552.94. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, COO Kaitlin M. Kestenberg-Messina sold 24,150 shares of the firm’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $16.90, for a total transaction of $408,135.00. Following the completion of the transaction, the chief operating officer now directly owns 449,088 shares in the company, valued at $7,589,587.20. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Adam S. Grossman sold 236,889 shares of the firm’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $17.69, for a total value of $4,190,566.41. Following the transaction, the chief executive officer now owns 2,059,726 shares of the company’s stock, valued at $36,436,552.94. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 466,900 shares of company stock valued at $8,224,121. 3.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On ADMA Biologics

Several large investors have recently bought and sold shares of the business. USA Financial Formulas increased its holdings in ADMA Biologics by 8.6% in the 3rd quarter. USA Financial Formulas now owns 6,817 shares of the biotechnology company’s stock worth $136,000 after buying an additional 539 shares in the last quarter. Vontobel Holding Ltd. increased its holdings in ADMA Biologics by 7.0% in the 3rd quarter. Vontobel Holding Ltd. now owns 13,643 shares of the biotechnology company’s stock worth $273,000 after buying an additional 888 shares in the last quarter. Viewpoint Capital Management LLC increased its holdings in ADMA Biologics by 18.6% in the 1st quarter. Viewpoint Capital Management LLC now owns 15,416 shares of the biotechnology company’s stock worth $102,000 after buying an additional 2,416 shares in the last quarter. Quest Partners LLC bought a new stake in ADMA Biologics in the 2nd quarter worth about $29,000. Finally, Arizona State Retirement System increased its holdings in ADMA Biologics by 4.5% in the 2nd quarter. Arizona State Retirement System now owns 61,641 shares of the biotechnology company’s stock worth $689,000 after buying an additional 2,645 shares in the last quarter. 75.68% of the stock is currently owned by institutional investors.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.